JP2023520469A5 - - Google Patents

Info

Publication number
JP2023520469A5
JP2023520469A5 JP2022559934A JP2022559934A JP2023520469A5 JP 2023520469 A5 JP2023520469 A5 JP 2023520469A5 JP 2022559934 A JP2022559934 A JP 2022559934A JP 2022559934 A JP2022559934 A JP 2022559934A JP 2023520469 A5 JP2023520469 A5 JP 2023520469A5
Authority
JP
Japan
Prior art keywords
fenebrutinib
pharmaceutically acceptable
acceptable salt
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022559934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025301 external-priority patent/WO2021202825A1/en
Publication of JP2023520469A publication Critical patent/JP2023520469A/ja
Publication of JP2023520469A5 publication Critical patent/JP2023520469A5/ja
Pending legal-status Critical Current

Links

JP2022559934A 2020-04-03 2021-04-01 ブルトン型チロシンキナーゼの阻害剤を使用する再発性多発性硬化症の治療方法 Pending JP2023520469A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063005095P 2020-04-03 2020-04-03
US63/005,095 2020-04-03
US202063051767P 2020-07-14 2020-07-14
US63/051,767 2020-07-14
PCT/US2021/025301 WO2021202825A1 (en) 2020-04-03 2021-04-01 Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026071127A Division JP2026133417A (ja) 2020-04-03 2026-04-22 ブルトン型チロシンキナーゼの阻害剤を使用する再発性多発性硬化症の治療方法

Publications (2)

Publication Number Publication Date
JP2023520469A JP2023520469A (ja) 2023-05-17
JP2023520469A5 true JP2023520469A5 (cg-RX-API-DMAC7.html) 2024-04-10

Family

ID=75625678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559934A Pending JP2023520469A (ja) 2020-04-03 2021-04-01 ブルトン型チロシンキナーゼの阻害剤を使用する再発性多発性硬化症の治療方法

Country Status (13)

Country Link
US (1) US12605376B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125906A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023520469A (cg-RX-API-DMAC7.html)
KR (1) KR20220163986A (cg-RX-API-DMAC7.html)
CN (1) CN115916205A (cg-RX-API-DMAC7.html)
AU (1) AU2021249129B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019846A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177390A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002699A1 (cg-RX-API-DMAC7.html)
IL (1) IL296990A (cg-RX-API-DMAC7.html)
MX (1) MX2022012310A (cg-RX-API-DMAC7.html)
TW (1) TWI907406B (cg-RX-API-DMAC7.html)
WO (1) WO2021202825A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI899163B (zh) * 2020-02-28 2025-10-01 美商建南德克公司 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
BR112023021235A2 (pt) 2021-05-14 2023-12-12 Loxo Oncology Inc Formas cocristalinas de um inibidor da tirosina quinase de bruton
CN114028393B (zh) * 2021-11-07 2023-07-18 天津医科大学 阿帕替尼在制备治疗多发性硬化症药物的用途
WO2024238524A1 (en) * 2023-05-16 2024-11-21 Genentech, Inc. Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
PL4049660T3 (pl) 2016-02-29 2025-06-09 F. Hoffmann-La Roche Ag Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona
CN107043366B (zh) 2017-04-25 2020-05-26 中国药科大学 4-氨基嘧啶类化合物、其制备方法及医药用途
EP3626239B1 (en) 2017-05-18 2024-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ezh2 inhibitor combined with btk inhibitor for treating tumor
US20210113568A1 (en) * 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
JP2022500408A (ja) * 2018-09-12 2022-01-04 デノボ バイオファーマ エルエルシー エンザスタウリンとbtkの阻害剤との組合せおよびその使用
EP3914250A1 (en) 2019-01-22 2021-12-01 F. Hoffmann-La Roche AG Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
TWI899163B (zh) 2020-02-28 2025-10-01 美商建南德克公司 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法

Similar Documents

Publication Publication Date Title
JP7807870B2 (ja) うつ病の治療のためのエスケタミン
US20220152056A1 (en) Methods and compositions for treating various disorders
JP6014655B2 (ja) うつ病および不安を予防し治療するためのタペンタドール
US12090148B2 (en) Treatment of migraine
EP3206682B1 (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
CN105311029A (zh) 抗肿瘤活性的喹啉衍生物
WO2022177718A1 (en) Use of neuroactive steroid for treatment of sexual dysfunction
JP2018502898A (ja) 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および/または代謝疾患の処置のための、脳由来神経栄養因子(bdnf)の誘導された発現
AU2021205465A1 (en) Methods of treating conditions related to the S1P1 receptor
TW201204360A (en) Treatment of multiple sclerosis with MASITINIB
US20220395472A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
JP2022532098A5 (cg-RX-API-DMAC7.html)
JP2025513240A5 (cg-RX-API-DMAC7.html)
Frackiewicz et al. Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa
JP2021530568A5 (cg-RX-API-DMAC7.html)
KR20100002304A (ko) 안진 치료용 네라멕산
JP7219476B2 (ja) 腱滑膜病変を主体とした疾患の治療薬
US20200038414A1 (en) Methods of treating constipation using aminosterol compositions
RU2022127814A (ru) Способы лечения рецидивирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
CA3100635A1 (en) Combinations comprising tropifexor and cenicriviroc
JP2022546042A5 (cg-RX-API-DMAC7.html)
TW201932114A (zh) 化合物用於炎症介導的視神經病變的治療
KR20250160957A (ko) 척수성 근위축증의 치료를 위한 조성물 및 방법
WO2025018279A1 (ja) ヒト移植片対宿主病の治療薬およびその組合せ物
WO2025096942A1 (en) Trimeprazine for use in treating pain associated with trigeminal neuralgia